JP2010529999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529999A5 JP2010529999A5 JP2010512385A JP2010512385A JP2010529999A5 JP 2010529999 A5 JP2010529999 A5 JP 2010529999A5 JP 2010512385 A JP2010512385 A JP 2010512385A JP 2010512385 A JP2010512385 A JP 2010512385A JP 2010529999 A5 JP2010529999 A5 JP 2010529999A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polysorbate
- phosphate buffer
- sodium chloride
- sodium phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 229940068968 Polysorbate 80 Drugs 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000012064 sodium phosphate buffer Substances 0.000 claims 3
- 108010035649 Natalizumab Proteins 0.000 claims 2
- 229960005027 natalizumab Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
Claims (7)
- 約120mg/ml〜約190mg/mlの濃度のナタリズマブ、約1mM〜約100mMのリン酸ナトリウム緩衝剤、約50mM〜約200mMの塩化ナトリウム、約0.01％〜0.12％のポリソルベート80を含み、かつpHが6±1.0である、水性医薬組成物。
- 約10mMのリン酸ナトリウム緩衝剤を含む、請求項1記載の組成物。
- 約140mMの塩化ナトリウムを含む、請求項1記載の組成物。
- 約0.04％（w/v）のポリソルベート80を含む、請求項1記載の組成物。
- 約0.02％（w/v）のポリソルベート80を含む、請求項1記載の組成物。
- pHが6.0±0.5である、請求項1記載の組成物。
- 約150mg/mlのナタリズマブ、約10mMのリン酸ナトリウム緩衝剤、約140mMの塩化ナトリウム、及び、約0.04％（w/v）のポリソルベート80を含み、pHが約6±0.5である、水性医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94407607P | 2007-06-14 | 2007-06-14 | |
| PCT/US2008/066928 WO2008157356A2 (en) | 2007-06-14 | 2008-06-13 | Antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013182749A Division JP2014040424A (ja) | 2007-06-14 | 2013-09-04 | 抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010529999A JP2010529999A (ja) | 2010-09-02 |
| JP2010529999A5 true JP2010529999A5 (ja) | 2011-07-28 |
Family
ID=39956053
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512385A Pending JP2010529999A (ja) | 2007-06-14 | 2008-06-13 | 抗体製剤 |
| JP2013182749A Pending JP2014040424A (ja) | 2007-06-14 | 2013-09-04 | 抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013182749A Pending JP2014040424A (ja) | 2007-06-14 | 2013-09-04 | 抗体製剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20080311119A1 (ja) |
| EP (2) | EP3461500A1 (ja) |
| JP (2) | JP2010529999A (ja) |
| CN (2) | CN103977404A (ja) |
| AR (2) | AR067011A1 (ja) |
| AU (1) | AU2008266051B2 (ja) |
| BR (1) | BRPI0814252B8 (ja) |
| CA (1) | CA2690382A1 (ja) |
| CY (1) | CY1121208T1 (ja) |
| DK (1) | DK2170390T3 (ja) |
| EA (1) | EA020456B1 (ja) |
| ES (1) | ES2707815T3 (ja) |
| HR (1) | HRP20182146T1 (ja) |
| HU (1) | HUE041555T2 (ja) |
| IL (1) | IL202648B (ja) |
| LT (1) | LT2170390T (ja) |
| MX (2) | MX2009013593A (ja) |
| NZ (2) | NZ595526A (ja) |
| PL (1) | PL2170390T3 (ja) |
| PT (1) | PT2170390T (ja) |
| SI (1) | SI2170390T1 (ja) |
| TR (1) | TR201820837T4 (ja) |
| TW (1) | TWI614028B (ja) |
| WO (1) | WO2008157356A2 (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY162623A (en) | 2003-02-10 | 2017-06-30 | Biogen Ma Inc | Immunoglobulin formulation and method of preparation thereof |
| JP2012533548A (ja) * | 2009-07-14 | 2012-12-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 組成物における黄色形成および過酸化物形成を阻害する方法 |
| EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
| CA3101298A1 (en) | 2010-03-01 | 2011-09-09 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| AU2011239512B2 (en) | 2010-04-16 | 2016-01-21 | Biogen Ma Inc. | Anti-VLA-4 antibodies |
| US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
| WO2013006461A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Cholesterol-based media supplementals for cell culture |
| AR088383A1 (es) * | 2011-10-18 | 2014-05-28 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles |
| US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
| US10160808B2 (en) * | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
| NZ702342A (en) * | 2012-06-21 | 2016-07-29 | Ucb Pharma Sa | Pharmaceutical formulation |
| EP2869816A4 (en) | 2012-07-09 | 2016-04-20 | Coherus Biosciences Inc | FORMANTS OF ETANERCEPT HAVING A REDUCTION MARKED IN INVISIBLE PARTICLES IN THE NU |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| AU2013315750B9 (en) | 2012-09-11 | 2018-11-15 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
| CN103217525B (zh) * | 2013-03-21 | 2015-04-29 | 上海执诚生物科技股份有限公司 | 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途 |
| WO2015063180A1 (en) * | 2013-10-29 | 2015-05-07 | Novozymes Biopharma Dk A/S | Antibody composition |
| CN111402950B (zh) * | 2013-11-29 | 2024-03-19 | 豪夫迈·罗氏有限公司 | 抗体选择装置和方法 |
| KR20160131073A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg4-5에 대해 특이적인 항-라미닌4 항체 |
| CA2938945A1 (en) * | 2014-03-13 | 2015-09-17 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| MX2016015893A (es) * | 2014-06-02 | 2017-03-20 | Lab Francais Du Fractionnement | Produccion de fragmentos de fragmento cristalizable (fc). |
| WO2016059512A1 (en) * | 2014-10-18 | 2016-04-21 | Pfizer Inc. | Anti-il-7r antibody compositions |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372241A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| BR112022000026A2 (pt) * | 2019-07-10 | 2022-06-07 | Regeneron Pharma | Métodos e composições compreendendo nível reduzido de proteínas de células hospedeiras |
| TW202227483A (zh) * | 2020-10-30 | 2022-07-16 | 日商衛材R&D企管股份有限公司 | 醫藥組合物 |
| US20230416373A1 (en) | 2020-11-14 | 2023-12-28 | Biogen Ma Inc. | Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies |
| JP2024513974A (ja) | 2021-04-13 | 2024-03-27 | バイオジェン・エムエイ・インコーポレイテッド | 慢性活動性白質病変／放射線学的孤立性症候群を治療するための組成物及び方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| JPS62196921A (ja) | 1986-02-25 | 1987-08-31 | Nec Corp | 位相検出回路 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| SG47043A1 (en) | 1993-01-06 | 1998-03-20 | Kinerton Ltd | Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides |
| DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
| AU687790B2 (en) | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| KR100367948B1 (ko) * | 1994-01-25 | 2003-07-12 | 엘란 파마슈티칼스, 인크. | 백혈구부착분자vla-4에대한인체화된항체 |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DE19541844C1 (de) * | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| WO2001055112A1 (en) | 2000-01-27 | 2001-08-02 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| MY162623A (en) * | 2003-02-10 | 2017-06-30 | Biogen Ma Inc | Immunoglobulin formulation and method of preparation thereof |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CN103169965A (zh) * | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
| EP2053961A4 (en) | 2006-08-09 | 2013-05-01 | Biogen Idec Inc | METHOD FOR DISPENSING A MEDICAMENT |
-
2008
- 2008-06-13 MX MX2009013593A patent/MX2009013593A/es active IP Right Grant
- 2008-06-13 AU AU2008266051A patent/AU2008266051B2/en active Active
- 2008-06-13 DK DK08771026.5T patent/DK2170390T3/en active
- 2008-06-13 NZ NZ595526A patent/NZ595526A/xx unknown
- 2008-06-13 EP EP18193307.8A patent/EP3461500A1/en active Pending
- 2008-06-13 AR ARP080102545A patent/AR067011A1/es not_active Application Discontinuation
- 2008-06-13 PT PT08771026T patent/PT2170390T/pt unknown
- 2008-06-13 WO PCT/US2008/066928 patent/WO2008157356A2/en active Application Filing
- 2008-06-13 CN CN201410163087.4A patent/CN103977404A/zh active Pending
- 2008-06-13 TR TR2018/20837T patent/TR201820837T4/tr unknown
- 2008-06-13 PL PL08771026T patent/PL2170390T3/pl unknown
- 2008-06-13 CA CA2690382A patent/CA2690382A1/en not_active Abandoned
- 2008-06-13 HU HUE08771026A patent/HUE041555T2/hu unknown
- 2008-06-13 NZ NZ582436A patent/NZ582436A/en unknown
- 2008-06-13 CN CN200880102434A patent/CN101778640A/zh active Pending
- 2008-06-13 EA EA201070015A patent/EA020456B1/ru unknown
- 2008-06-13 TW TW097122335A patent/TWI614028B/zh active
- 2008-06-13 EP EP08771026.5A patent/EP2170390B1/en active Active
- 2008-06-13 US US12/139,362 patent/US20080311119A1/en not_active Abandoned
- 2008-06-13 LT LTEP08771026.5T patent/LT2170390T/lt unknown
- 2008-06-13 SI SI200832029T patent/SI2170390T1/sl unknown
- 2008-06-13 BR BRPI0814252A patent/BRPI0814252B8/pt active IP Right Grant
- 2008-06-13 JP JP2010512385A patent/JP2010529999A/ja active Pending
- 2008-06-13 ES ES08771026T patent/ES2707815T3/es active Active
-
2009
- 2009-12-10 IL IL202648A patent/IL202648B/en active IP Right Grant
- 2009-12-11 MX MX2020005214A patent/MX2020005214A/es unknown
-
2012
- 2012-01-27 US US13/359,959 patent/US20120134989A1/en not_active Abandoned
- 2012-06-22 US US13/530,879 patent/US9533044B2/en active Active
-
2013
- 2013-09-04 JP JP2013182749A patent/JP2014040424A/ja active Pending
-
2018
- 2018-12-18 HR HRP20182146TT patent/HRP20182146T1/hr unknown
-
2019
- 2019-02-01 CY CY20191100146T patent/CY1121208T1/el unknown
- 2019-03-19 AR ARP190100691A patent/AR117403A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529999A5 (ja) | ||
| JP2010522208A5 (ja) | ||
| JP2011088913A5 (ja) | ||
| JP2016513069A5 (ja) | ||
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
| UA107557C2 (xx) | Композиція антитіла офатумумабу | |
| IL215275A0 (en) | Pharmaceutical formulations and methods for treating respiratory tract infections | |
| JP2012184234A5 (ja) | ||
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| JP2015527402A5 (ja) | ||
| JP2009531457A5 (ja) | ||
| HRP20240168T1 (hr) | Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije | |
| NZ597237A (en) | Sublingual apomorphine | |
| RU2009126767A (ru) | Производное 1-фенил-1-тио-d-глюцитола | |
| UY30021A1 (es) | Formulación de suspensión de fexofenadina | |
| JP2013508315A5 (ja) | ||
| JP2013510169A5 (ja) | ||
| CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
| JP2015535237A5 (ja) | ||
| JP2011512394A5 (ja) | ||
| JP2016510747A5 (ja) | ||
| PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno | |
| CY1120050T1 (el) | Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων | |
| JP2019513138A5 (ja) |